Neurolixis is proud to win the Occitanie Silver Trophées 2023 contest in the 'Innovation' category. Neurolixis was rewarded for the development of NLX-112, a new drug candidate for the treatment of Parkinson's disease which gave positive results in a Phase 2A proof-of-concept clinical trial. Parkinson's disease affects 9 million people worldwide and is the second most common neurodegenerative disease after Alzheimer's. Many thanks to La Région Occitanie / Pyrénées-Méditerranée and to The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK research foundations for their support!